ANDEMBRY®

Efficacy And Safety of Garadacimab Via Autoinjector/Pre-Filled Pen For Hereditary Angioedema Long-Term - AAAAI 2025

View Poster

Long-Term Efficacy of Garadacimab for Hereditary Angioedema in Patients With or Without Prior Exposure in a Phase 3 Open-Label Extension Study - AAAAI 2025

View Poster

Garadacimab Pharmacokinetic and Safety Profiles Show No Impact of Concomitant Medication Use in Hereditary Angioedema - AAAAI 2025

View Poster

Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis in Patients Aged ≥65 Years - AAAAI 2025

View Poster

Clinical Study Experience Suggests No Impact on Hemostasis Among Patients With Hereditary Angioedema Receiving Garadacimab and Undergoing Surgical/Medical Procedures - AAAAI 2025

View Poster

Real-World Analysis of Treatment Patterns Among Patients With Hereditary Angioedema in the United States - AAAAI 2025

View Poster

Garadacimab Real-World Treatment Outcomes of Effectiveness, Safety, and Quality-Of-Life in Patients With HAE (GREAT) Study Design - AAAAI 2025

View Poster

Characterization Of Injection Site-Related Adverse Events With Garadacimab In Patients With Hereditary Angioedema - ACAAI 2024

View Poster

Clinical Evidence With Garadacimab Demonstrates No Impact on Hemostasis - ACAAI 2024

View Poster

Pharmacometric Analysis Supports Early Onset of Protection With Garadacimab Against Hereditary Angioedema Attacks - ACAAI 2024

View Poster

Low Incidence of Garadacimab Immunogenicity With No Impact on Efficacy, Safety, or Pharmacokinetics: Integrated Analysis - ACAAI 2024

View Poster

Being Attack-Free With Garadacimab Improves Quality of Life in Patients With Hereditary Angioedema - ACAAI 2024

View Poster

Garadacimab provides early onset of protection against HAE attacks from Week 1 after first administration- EAACI 2024

View Poster

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study - EAACI 2024

View Poster

Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: Phase 2, pivotal Phase 3, and open-label extension studies - AAAAI 2024

View Poster

A Phase 1, Randomized, Open-Label, Parallel-Group Study Comparing Pharmacokinetic Properties of Garadacimab Administered by Subcutaneous Pre-filled Syringe Assembled to Autoinjector/Pre-filled Pen versus Pre-filled Syringe Assembled to Needle Safety Device in Healthy Adults - AAAAI 2024

View Poster

Population pharmacokinetic/pharmacodynamic analysis of garadacimab in patients with hereditary angioedema - AAAAI 2024

View Poster

Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis) - AAAAI 2024

View Poster

Long-term safety and efficacy with garadacimab for hereditary angioedema prophylaxis in an open-label extension study (second interim analysis) - WSAAI 2024

View Poster

Long-term quality-of-life and patient-reported improvements with garadacimab for hereditary angioedema: Phase 3 open-label extension study (NCT04739059) - ACAAI 2023

View Poster

Garadacimab for hereditary angioedema (HAE) prophylaxis: long-term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial

View Poster

Garadacimab for hereditary angioedema prophylaxis in adolescents: efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)

View Poster

Efficacy and safety of subcutaneous garadacimab for the prophylaxis of hereditary angioedema (HAE) attacks in adult and adolescent patients with HAE: results from a multicenter, placebo-controlled Phase 3 trial

View Poster

Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study

Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

Hereditary angioedema with normal C1 esterase inhibitor: Current paradigms and clinical dilemmas

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study